If You Invested in MBody AI Ltd. (MBAI)
Looking for the current price? See the MBAI quote & overviewWhat $1,000 or $10,000 in MBAI Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Nov 10, 2015 |
|---|---|---|---|---|
| $1,000 | $207 -79% | $16 -98% | $0.68 -99.93% | $0.55 -99.94% |
| $10,000 | $2,074 -79% | $164 -98% | $6.83 -99.93% | $5.52 -99.94% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-06. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for MBAI$1,000 Investment Over Time
MBAI vs S&P 500Year-by-Year Returns
MBAI annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015Nov 10, 2015 to Dec 31, 2015 | $4,368.00 | $3,175.20 | -27.3% | -27.3% |
| 2016 | $3,175.20 | $3,948.00 | +24.3% | -9.6% |
| 2017 | $3,948.00 | $1,461.60 | -63.0% | -66.5% |
| 2018 | $1,461.60 | $301.00 | -79.4% | -93.1% |
| 2019 | $301.00 | $240.80 | -20.0% | -94.5% |
| 2020 | $240.80 | $64.40 | -73.3% | -98.5% |
| 2021 | $64.40 | $94.50 | +46.7% | -97.8% |
| 2022 | $94.50 | $15.40 | -83.7% | -99.6% |
| 2023 | $15.40 | $14.56 | -5.5% | -99.7% |
| 2024 | $14.56 | $6.93 | -52.4% | -99.8% |
| 2025 | $6.93 | $11.34 | +63.6% | -99.7% |
| 2026Dec 31, 2025 to Nov 6, 2026 | $11.34 | $2.41 | -78.7% | -99.9% |
About MBody AI Ltd.
Technology · NASDAQ
MBAI is the Nasdaq ticker symbol for the public company associated with MBody AI Corp. and Check-Cap Ltd. According to available information, the ticker symbol changed from "CHEK" to "MBAI" as part of a previously announced and approved merger process. This transition reflects the company’s move from its historical focus under the Check-Cap name toward operating as an embodied artificial intelligence business connected with MBody AI.
The company’s transformation is described as a step in its transition into a global leader in embodied artificial intelligence. The merger-related change in ticker symbol to MBAI is intended to align the public listing with this new strategic direction. Existing shareholders were informed that no action was required on their part in connection with the ticker change and that the company’s CUSIP number would remain the same.
MBody AI is described as a global market leader in embodied artificial intelligence, with a proprietary, hardware-agnostic orchestration technology stack. This technology, referred to as the MBody AI Orchestrator™, integrates robotic and sensor-based systems across multiple industries. The platform is designed to coordinate robots, sensors, autonomous carts, autonomous mobile robots (AMRs), and facility-wide automation systems through a single enterprise-grade AI layer. The company’s approach is compared to how cloud platforms abstract software from underlying hardware, but applied to physical AI systems.
Available information notes that MBody AI’s platform is already deployed across Fortune 500 enterprises and blue-chip clients. The company’s strategy focuses on enabling physical automation at scale in environments such as hospitality, healthcare, logistics, retail, and industrial settings. The broader context described around embodied AI highlights factors such as labor shortages, rising compliance and safety requirements, and the potential for recurring cost and efficiency gains from physical AI deployments.
Historically, Check-Cap Ltd. has been described as a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers. It has been associated with the development of C-Scan, described as a capsule-based system for preparation-free colorectal cancer screening. That business description reflects the company’s earlier focus prior to the merger-related transition toward embodied artificial intelligence under the MBAI ticker.
The available information also indicates that the operations of Check-Cap Ltd. were located in Israel, with an expectation to market products in the United States, Europe, Israel, and Japan. In the more recent description associated with the MBAI ticker, locations referenced include Las Vegas, Nevada and Isfiya, Israel in connection with the announcement of the ticker change and the company’s embodied AI strategy.
Overall, MBAI represents the public market identity of the combined enterprise emerging from the merger process between MBody AI Corp. and Check-Cap Ltd. The historical Check-Cap medical diagnostics activities and the newer embodied AI platform orientation coexist in the record as part of the company’s corporate evolution. Investors researching MBAI should recognize that the ticker reflects this transition from a clinical-stage medical diagnostics profile toward an embodied artificial intelligence platform associated with MBody AI.
Similar Stocks
See how related companies performed
Frequently Asked Questions
MBody AI Ltd. investment returns
How much would $1,000 invested in MBody AI Ltd. be worth today?
If you invested $1,000 in MBody AI Ltd. (MBAI) 10 years ago on 2016-11-07, your investment would be worth $0.68 as of 2026-11-06, a -99.9% price return without dividends, growing at a compounded rate of -51.8% per year (CAGR).
Has MBody AI Ltd. outperformed the S&P 500?
Over the past 10 years, MBAI returned -99.9% compared to +245.0% for the S&P 500, underperforming the benchmark by 344.9 percentage points.
What is MBody AI Ltd.'s average annual return?
The compound annual growth rate (CAGR) of MBAI’s share price over the past 10 years is -51.8%, without dividends. Individual years vary a great deal, and MBAI’s best recent full year was 2025 (+63.6%) while the worst was 2022 (-83.7%).
For informational and educational purposes only, not investment advice.
